2-[(biphenyl-4-ylcarbonyl)amino]-5-chlorobenzoic acid | 905363-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(biphenyl-4-ylcarbonyl)amino]-5-chlorobenzoic acid
• 英文别名: 5-Chloro-2-[(4-phenylbenzoyl)amino]benzoic acid；5-chloro-2-[(4-phenylbenzoyl)amino]benzoic acid
• CAS: 905363-96-4
• 化学式: C₂₀H₁₄ClNO₃
• 分子量: 351.789
• InChiKey: YJZXKAQCQFUJDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-5-氯苯甲酸 在 吡啶 、 4-二甲氨基吡啶 、 氯化亚砜 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 36.0h， 生成 2-[(biphenyl-4-ylcarbonyl)amino]-5-chlorobenzoic acid
  参考文献：
  名称：

  Discovery of Novel Bacterial RNA Polymerase Inhibitors: Pharmacophore-Based Virtual Screening and Hit Optimization

  摘要：

  The bacterial RNA polymerase (RNAP) is a validated target for broad spectrum antibiotics. However, the efficiency of drugs is reduced by resistance. To discover novel RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used for virtual screening. In an optimization process of hit compounds, novel derivatives with improved in vitro potency were discovered. Investigations concerning the molecular mechanism of RNAP inhibition reveal that they prevent the protein-protein interaction (PPI) between sigma(70) and the RNAP core enzyme. Besides of reducing RNA formation, the inhibitors were shown to interfere with bacterial lipid biosynthesis. The compounds were active against Gram-positive pathogens and revealed significantly lower resistance frequencies rifampicin.

  DOI：

  10.1021/jm400485e

文献信息

• Identification of novel plasminogen activator inhibitor-1 inhibitors with improved oral bioavailability: Structure optimization of N-acylanthranilic acid derivatives
  作者：Nagahisa Yamaoka、Kenji Murano、Hidehiko Kodama、Akihisa Maeda、Takashi Dan、Tetsuo Nakabayashi、Toshio Miyata、Kanji Meguro

  DOI：10.1016/j.bmcl.2017.11.016

  日期：2018.2

  compounds in which 5-chloroanthranilic acid was bound to a variety of highly lipophilic moieties with appropriate linkers was investigated. As the result it appeared that some of the derivatives possessing aryl- or heteroaryl-substituted phenyl groups in the acyl chain had potent in vitro PAI-1 inhibitory activity. Oral absorbability of typical compounds was also evaluated in rats, and compounds 40,

  通过对N-酰基-5-氯邻氨基苯甲酸衍生物的结构-活性关系研究发现了新型的具有显着改善的口服生物利用度的纤溶酶原激活物抑制剂-1（PAI-1）抑制剂。由于亲脂性N-酰基对于邻氨基苯甲酸衍生物强烈抑制PAI-1似乎很重要，因此研究了其中5-氯邻氨基苯甲酸与各种具有适当连接基的高度亲脂性部分结合的化合物的合成。结果表明，某些在酰基链上具有被芳基或杂芳基取代的苯基的衍生物具有有效的体外PAI-1抑制活性。还评估了大鼠中典型化合物的口服吸收能力，化合物40，55，60和76被选择具有相互不同的化学结构，用于进一步药理评价。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Miyata Toshio

  公开号：US20120022080A1

  公开（公告）日：2012-01-26

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活物抑制剂-1抑制活性的新化合物，以及包括该化合物作为活性成分的PAI-1抑制剂。本发明还提供了一种对PAI-1活性具有抑制作用且在预防和治疗与PAI-1活性相关的各种疾病方面有效的药物组合物。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
  申请人：RENASCIENCE CO., LTD.

  公开号：US20140296256A1

  公开（公告）日：2014-10-02

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活抑制剂-1抑制活性的新型化合物，以及以该化合物为活性成分的PAI-1抑制剂。本发明还提供了一种具有抑制PAI-1活性并在预防和治疗与PAI-1活性相关的各种疾病方面具有疗效的药物组合物。
• NOVEL USE FOR PAI-1 INHIBITOR
  申请人：Renascience Co., Ltd.

  公开号：EP2990057A1

  公开（公告）日：2016-03-02

  Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.

  本发明提供了一种纤溶酶原激活物抑制剂-1 抑制剂（PAI-1 抑制剂）的新用途，该抑制剂可用作控制肿瘤干细胞的药物、增强抗肿瘤药物抗肿瘤效果的药物、肿瘤化疗药物、干细胞保护药物或改善造血障碍药物的活性成分。
• Use for PAI-1 inhibitor
  申请人：RENASCIENCE CO., LTD.

  公开号：US10092537B2

  公开（公告）日：2018-10-09

  Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.

  本发明提供了一种纤溶酶原激活物抑制剂-1 抑制剂（PAI-1 抑制剂）的新用途，该抑制剂可用作控制肿瘤干细胞的药物、增强抗肿瘤药物抗肿瘤效果的药物、肿瘤化疗药物、干细胞保护药物或改善造血障碍药物的活性成分。